The Cell-Cycle Arrest and Apoptotic Functions of P53 in Tumor Initiation and Progression

Overview

Journal Cold Spring Harb Perspect Med

Specialty General Medicine

Date 2016 Mar 3

PMID 26931810

Citations 479

Authors

Jiandong Chen

Affiliations

Soon will be listed here.

Abstract

P53 is a transcription factor highly inducible by many stress signals such as DNA damage, oncogene activation, and nutrient deprivation. Cell-cycle arrest and apoptosis are the most prominent outcomes of p53 activation. Many studies showed that p53 cell-cycle and apoptosis functions are important for preventing tumor development. p53 also regulates many cellular processes including metabolism, antioxidant response, and DNA repair. Emerging evidence suggests that these noncanonical p53 activities may also have potent antitumor effects within certain context. This review focuses on the cell-cycle arrest and apoptosis functions of p53, their roles in tumor suppression, and the regulation of cell fate decision after p53 activation.

Citing Articles

Exploring the potential link between human papillomavirus infection and coronary artery disease: a review of shared pathways and mechanisms.

Saha D, Dutta P, Rebello K, Shankar A, Chakraborty A Mol Cell Biochem. 2025; .

PMID: 40045143 DOI: 10.1007/s11010-025-05236-9.

CeDaD-a novel assay for simultaneous tracking of cell death and division in a single population.

Noltner L, Engeland K, Kohler R Cell Death Discov. 2025; 11(1):86.

PMID: 40038265 PMC: 11880512. DOI: 10.1038/s41420-025-02370-7.

Effect of palliative radiotherapy and cyclin-dependent kinase 4/6 inhibitor on breast cancer cell lines.

Sharaky M, El Kiki S, Effat H, Mansour H Naunyn Schmiedebergs Arch Pharmacol. 2025; .

PMID: 40035822 DOI: 10.1007/s00210-025-03878-6.

EPAS1 induction drives myocardial degeneration in desmoplakin-cardiomyopathy.

Kyriakopoulou E, van Kampen S, Wehrens M, Han S, de Ruiter H, Monshouwer-Kloots J iScience. 2025; 28(3):111895.

PMID: 40034852 PMC: 11872638. DOI: 10.1016/j.isci.2025.111895.

A new insight into the impact of copy number variations on cell cycle deregulation of luminal-type breast cancer.

Mahdi Khamaneh A, Jafari-Gharabaghlou D, Ansarin K, Pazooki P, Akbarpour Z, Naghili B Oncol Rev. 2025; 19:1516409.

PMID: 40017494 PMC: 11861078. DOI: 10.3389/or.2025.1516409.

References

Schlereth K, Beinoraviciute-Kellner R, Zeitlinger M, Bretz A, Sauer M, Charles J . DNA binding cooperativity of p53 modulates the decision between cell-cycle arrest and apoptosis. Mol Cell. 2010; 38(3):356-68. DOI: 10.1016/j.molcel.2010.02.037. View

Mao J, Wu D, Kim I, Kang H, Wei G, Climent J . Hipk2 cooperates with p53 to suppress γ-ray radiation-induced mouse thymic lymphoma. Oncogene. 2011; 31(9):1176-80. PMC: 3307058. DOI: 10.1038/onc.2011.306. View

Chang B, Broude E, Dokmanovic M, Zhu H, Ruth A, Xuan Y . A senescence-like phenotype distinguishes tumor cells that undergo terminal proliferation arrest after exposure to anticancer agents. Cancer Res. 1999; 59(15):3761-7. View

Kaeser M, Iggo R . Chromatin immunoprecipitation analysis fails to support the latency model for regulation of p53 DNA binding activity in vivo. Proc Natl Acad Sci U S A. 2002; 99(1):95-100. PMC: 117520. DOI: 10.1073/pnas.012283399. View

Tomita Y, Marchenko N, Erster S, Nemajerova A, Dehner A, Klein C . WT p53, but not tumor-derived mutants, bind to Bcl2 via the DNA binding domain and induce mitochondrial permeabilization. J Biol Chem. 2006; 281(13):8600-6. DOI: 10.1074/jbc.M507611200. View

Rowan S, Ludwig R, Haupt Y, Bates S, Lu X, Oren M . Specific loss of apoptotic but not cell-cycle arrest function in a human tumor derived p53 mutant. EMBO J. 1996; 15(4):827-38. PMC: 450281. View

Okoshi R, Ozaki T, Yamamoto H, Ando K, Koida N, Ono S . Activation of AMP-activated protein kinase induces p53-dependent apoptotic cell death in response to energetic stress. J Biol Chem. 2007; 283(7):3979-87. DOI: 10.1074/jbc.M705232200. View

Campisi J . Senescent cells, tumor suppression, and organismal aging: good citizens, bad neighbors. Cell. 2005; 120(4):513-22. DOI: 10.1016/j.cell.2005.02.003. View

Cain C, Miller S, Ahn J, Prives C . The N terminus of p53 regulates its dissociation from DNA. J Biol Chem. 2000; 275(51):39944-53. DOI: 10.1074/jbc.M002509200. View

10.

Narita M, Nunez S, Heard E, Narita M, Lin A, Hearn S . Rb-mediated heterochromatin formation and silencing of E2F target genes during cellular senescence. Cell. 2003; 113(6):703-16. DOI: 10.1016/s0092-8674(03)00401-x. View

11.

Tarasov V, Jung P, Verdoodt B, Lodygin D, Epanchintsev A, Menssen A . Differential regulation of microRNAs by p53 revealed by massively parallel sequencing: miR-34a is a p53 target that induces apoptosis and G1-arrest. Cell Cycle. 2007; 6(13):1586-93. DOI: 10.4161/cc.6.13.4436. View

12.

OConnor D, Bergamaschi D, Trigiante G, Hsieh J, Zhong S, Campargue I . ASPP proteins specifically stimulate the apoptotic function of p53. Mol Cell. 2001; 8(4):781-94. DOI: 10.1016/s1097-2765(01)00367-7. View

13.

Clarke A, Purdie C, Harrison D, Morris R, Bird C, Hooper M . Thymocyte apoptosis induced by p53-dependent and independent pathways. Nature. 1993; 362(6423):849-52. DOI: 10.1038/362849a0. View

14.

Gembarska A, Luciani F, Fedele C, Russell E, Dewaele M, Villar S . MDM4 is a key therapeutic target in cutaneous melanoma. Nat Med. 2012; 18(8):1239-47. PMC: 3744207. DOI: 10.1038/nm.2863. View

15.

Ventura A, Kirsch D, McLaughlin M, Tuveson D, Grimm J, Lintault L . Restoration of p53 function leads to tumour regression in vivo. Nature. 2007; 445(7128):661-5. DOI: 10.1038/nature05541. View

16.

Petros A, Gunasekera A, Xu N, Olejniczak E, Fesik S . Defining the p53 DNA-binding domain/Bcl-x(L)-binding interface using NMR. FEBS Lett. 2004; 559(1-3):171-4. DOI: 10.1016/S0014-5793(04)00059-6. View

17.

Chang B, Xuan Y, Broude E, Zhu H, Schott B, Fang J . Role of p53 and p21waf1/cip1 in senescence-like terminal proliferation arrest induced in human tumor cells by chemotherapeutic drugs. Oncogene. 1999; 18(34):4808-18. DOI: 10.1038/sj.onc.1203078. View

18.

Croxton R, Ma Y, Song L, Haura E, Cress W . Direct repression of the Mcl-1 promoter by E2F1. Oncogene. 2002; 21(9):1359-69. DOI: 10.1038/sj.onc.1205157. View

19.

Luo Y, Hurwitz J, Massague J . Cell-cycle inhibition by independent CDK and PCNA binding domains in p21Cip1. Nature. 1995; 375(6527):159-61. DOI: 10.1038/375159a0. View

20.

Ringshausen I, OShea C, Finch A, Swigart L, Evan G . Mdm2 is critically and continuously required to suppress lethal p53 activity in vivo. Cancer Cell. 2006; 10(6):501-14. DOI: 10.1016/j.ccr.2006.10.010. View